DDInter1538 DDInter1676
Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Propofol {u} (Compound) resembles {v} (Compound) Fospropofol
Propofol {u} (Compound) treats {v} (Disease) epilepsy syndrome
Propofol {u} (Compound) binds {v} (Gene) CYP2B6
Propofol {u} (Compound) is included by {v} (Pharmacologic Class) General Anesthesia
Propofol {u} (Compound) downregulates {v} (Gene) NPDC1
Propofol {u} (Compound) causes {v} (Side Effect) Bronchospasm
Propofol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dyphylline
Propofol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Astemizole
Propofol (Compound) resembles Fospropofol (Compound)
Propofol (Compound) treats epilepsy syndrome (Disease)
Propofol (Compound) binds CYP2B6 (Gene)
Propofol (Compound) is included by General Anesthesia (Pharmacologic Class)
Propofol (Compound) downregulates NPDC1 (Gene)
Propofol (Compound) causes Bronchospasm (Side Effect)
Propofol may cause a minor interaction that can limit clinical effects when taken with Dyphylline
Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Astemizole